Diplomat Pharmacy Stock Price, News & Analysis (NYSE:DPLO)

$24.10 +0.29 (+1.22 %)
(As of 02/20/2018 04:48 AM ET)
Previous Close$23.81
Today's Range$23.79 - $24.45
52-Week Range$13.39 - $27.78
Volume610,400 shs
Average Volume925,358 shs
Market Capitalization$1.66 billion
P/E Ratio200.83
Dividend YieldN/A
Beta1.05

About Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy logoDiplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company's primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company's patient care system is used to coordinate and track patient adherence and safety.

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Healthcare Facilities & Services
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:DPLO
CUSIPN/A
Phone+1-888-7204450

Debt

Debt-to-Equity Ratio0.18%
Current Ratio1.34%
Quick Ratio0.82%

Price-To-Earnings

Trailing P/E Ratio200.833333333333
Forward P/E Ratio28.35
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.41 billion
Price / Sales0.38
Cash Flow$1.54 per share
Price / Cash15.68
Book Value$9.20 per share
Price / Book2.62

Profitability

Trailing EPS$0.12
Net Income$28.27 million
Net Margins0.18%
Return on Equity8.30%
Return on Assets4.70%

Miscellaneous

Employees1,827
Outstanding Shares68,870,000

Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) released its quarterly earnings results on Monday, November, 6th. The company reported $0.25 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.15 by $0.10. The business had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.16 billion. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The company's revenue was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.21 earnings per share. View Diplomat Pharmacy's Earnings History.

When will Diplomat Pharmacy make its next earnings announcement?

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Diplomat Pharmacy.

Where is Diplomat Pharmacy's stock going? Where will Diplomat Pharmacy's stock price be in 2018?

10 equities research analysts have issued 12-month target prices for Diplomat Pharmacy's stock. Their predictions range from $17.00 to $35.00. On average, they expect Diplomat Pharmacy's share price to reach $23.95 in the next year. View Analyst Ratings for Diplomat Pharmacy.

What are Wall Street analysts saying about Diplomat Pharmacy stock?

Here are some recent quotes from research analysts about Diplomat Pharmacy stock:

  • 1. According to Zacks Investment Research, "Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. " (10/10/2017)
  • 2. Mizuho analysts commented, "We are reiterating our price target of $17 while lowering our 2017E and 2018E adjusted EPS to $0.62 and $0.75, respectively. We think initial 2017 guidance removed an overhang. Further, assumptions embedded in guidance, including drug price inflation and DIR payments, appear conservative which reduces the risk of further guidance reductions throughout the year in our view." (3/1/2017)

Who are some of Diplomat Pharmacy's key competitors?

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:

  • Benjamin Wolin, Chairman of the Board (Age 42)
  • Joel Saban, President (Age 50)
  • Atul Kavthekar, Chief Financial Officer (Age 49)
  • Robyn Peters, Executive Vice President of Sales and Payor Strategies
  • Gary Rice, Executive Vice President - Operations (Age 59)
  • Philip R. Hagerman, Chairman Emeritus (Age 64)
  • Regina M. Benjamin M.D., Independent Director (Age 60)
  • David C. Dreyer CPA, Independent Director (Age 60)
  • Kenneth O. Klepper, Independent Director (Age 63)
  • Shawn Cline Tomasello, Independent Director (Age 58)

Who owns Diplomat Pharmacy stock?

Diplomat Pharmacy's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.81%), Frontier Capital Management Co. LLC (5.55%), Cortina Asset Management LLC (2.06%), Riverbridge Partners LLC (1.81%), GW&K Investment Management LLC (1.46%) and Phocas Financial Corp. (0.96%). Company insiders that own Diplomat Pharmacy stock include Atheer A Kaddis, Atul Kavthekar, Jeffrey G Park and Joel Saban. View Institutional Ownership Trends for Diplomat Pharmacy.

Who sold Diplomat Pharmacy stock? Who is selling Diplomat Pharmacy stock?

Diplomat Pharmacy's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Frontier Capital Management Co. LLC, GW&K Investment Management LLC, Cortina Asset Management LLC, Victory Capital Management Inc., Guggenheim Capital LLC, Riverbridge Partners LLC and First Trust Advisors LP. View Insider Buying and Selling for Diplomat Pharmacy.

Who bought Diplomat Pharmacy stock? Who is buying Diplomat Pharmacy stock?

Diplomat Pharmacy's stock was purchased by a variety of institutional investors in the last quarter, including Phocas Financial Corp., BlackRock Inc., Tekla Capital Management LLC, Alliancebernstein L.P., State of Wisconsin Investment Board, Investors Research Corp, Convergence Investment Partners LLC and Cornerstone Capital Management Holdings LLC.. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

How do I buy Diplomat Pharmacy stock?

Shares of Diplomat Pharmacy can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of Diplomat Pharmacy stock can currently be purchased for approximately $24.10.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $1.66 billion and generates $4.41 billion in revenue each year. The company earns $28.27 million in net income (profit) each year or $0.12 on an earnings per share basis. Diplomat Pharmacy employs 1,827 workers across the globe.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S Saginaw St, FLINT, MI 48507-2683, United States. The company can be reached via phone at +1-888-7204450 or via email at [email protected]ke.com.


MarketBeat Community Rating for Diplomat Pharmacy (DPLO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  396
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Diplomat Pharmacy (NYSE:DPLO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyHoldHold
Consensus Rating Score: 2.402.502.132.09
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.95$20.56$18.81$17.89
Price Target Upside: 0.38% upside10.56% downside1.35% downside14.99% upside

Diplomat Pharmacy (NYSE:DPLO) Consensus Price Target History

Price Target History for Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE:DPLO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018Lake Street CapitalInitiated CoverageBuy -> Buy$35.00HighView Rating Details
2/2/2018Deutsche BankDowngradeBuy -> Hold$22.00 -> $29.00HighView Rating Details
1/25/2018Credit Suisse GroupUpgradeUnderperform -> Neutral$28.00LowView Rating Details
1/24/2018MizuhoSet Price TargetHold$25.00LowView Rating Details
1/8/2018Needham & Company LLCBoost Price TargetBuy$24.00 -> $26.00MediumView Rating Details
12/11/2017Leerink SwannUpgradeMarket Perform -> Outperform$23.00MediumView Rating Details
11/16/2017Robert W. BairdDowngradeOutperform -> Neutral$24.00 -> $18.00N/AView Rating Details
5/25/2017Bank of AmericaBoost Price TargetNeutral$17.00 -> $18.50LowView Rating Details
5/9/2017BarclaysSet Price TargetBuy$17.00 -> $20.00LowView Rating Details
5/9/2017CowenBoost Price TargetMarket Perform$12.00 -> $17.00MediumView Rating Details
11/3/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
11/3/2016Raymond James FinancialReiterated RatingOutperform -> Market PerformN/AView Rating Details
11/3/2016CitigroupDowngradeMarket PerformN/AView Rating Details
11/3/2016Avondale PartnersDowngradeOutperform -> Market PerformN/AView Rating Details
5/19/2016William BlairReiterated RatingOutperformN/AView Rating Details
5/10/2016Wells Fargo & CoReiterated RatingHoldN/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Diplomat Pharmacy (NYSE:DPLO) Earnings History and Estimates Chart

Earnings by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE DPLO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018$0.16N/AView Earnings Details
11/6/2017Q3 2017$0.15$0.25$1.16 billion$1.12 billionViewN/AView Earnings Details
8/7/2017Q2 2017$0.15$0.25$1.14 billion$1.13 billionViewListenView Earnings Details
5/8/2017Q1 2017$0.15$0.19$1.08 billion$1.08 billionViewListenView Earnings Details
2/28/2017Q416$0.16$0.08$1.18 billion$1.14 billionViewListenView Earnings Details
11/2/2016Q316$0.24$0.21$1.26 billion$1.18 billionViewN/AView Earnings Details
8/9/2016Q216$0.21$0.23$1.12 billion$1.09 billionViewN/AView Earnings Details
5/9/2016Q116$0.18$0.23$984.28 million$995.90 millionViewN/AView Earnings Details
2/29/2016Q415$0.20$0.21$969.70 million$987.00 millionViewListenView Earnings Details
11/3/2015Q315$0.16$0.26$928.86 million$946.90 millionViewN/AView Earnings Details
8/3/2015Q215$0.12$0.16$738.99 million$808.01 millionViewN/AView Earnings Details
5/11/2015Q115$0.08$0.09$629.60 million$625.00 millionViewListenView Earnings Details
3/2/2015Q414$0.06$0.08$603.70 million$603.67 millionViewN/AView Earnings Details
11/10/2014Q3 2014$0.15$595.53 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Diplomat Pharmacy (NYSE:DPLO) Earnings Estimates

2018 EPS Consensus Estimate: $1.09
2019 EPS Consensus Estimate: $1.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.24$0.28$0.26
Q2 20182$0.24$0.28$0.26
Q3 20182$0.24$0.32$0.28
Q4 20182$0.24$0.34$0.29
Q1 20191$0.38$0.38$0.38
Q2 20191$0.35$0.35$0.35
Q3 20191$0.39$0.39$0.39
Q4 20191$0.40$0.40$0.40
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Diplomat Pharmacy (NYSE:DPLO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Diplomat Pharmacy (NYSE DPLO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 30.20%
Institutional Ownership Percentage: 73.44%
Insider Trades by Quarter for Diplomat Pharmacy (NYSE:DPLO)
Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE DPLO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2017Atul KavthekarCFOBuy2,000$15.00$30,000.002,000View SEC Filing  
11/20/2017Jeffrey G ParkDirectorBuy3,000$15.46$46,380.007,640View SEC Filing  
11/20/2017Joel SabanPresidentBuy10,000$15.24$152,400.0012,000View SEC Filing  
9/15/2016Atheer A KaddisEVPSell20,000$30.12$602,400.0020,000View SEC Filing  
8/1/2016Atheer A KaddisEVPSell12,325$35.76$440,742.0012,325View SEC Filing  
7/1/2016Atheer A KaddisEVPSell12,325$35.04$431,868.0012,325View SEC Filing  
6/1/2016Atheer A KaddisEVPSell12,325$32.31$398,220.7512,325View SEC Filing  
5/2/2016Atheer A KaddisEVPSell12,325$30.17$371,845.2512,325View SEC Filing  
4/15/2016Atheer A KaddisEVPSell24,650$30.00$739,500.0024,650View SEC Filing  
2/12/2016Atheer A. KaddisEVPSell12,325$30.00$369,750.00View SEC Filing  
12/7/2015Philip R HagermanCEOSell2,300,000$33.60$77,280,000.00View SEC Filing  
12/1/2015Atheer A. KaddisSVPSell12,325$34.75$428,293.75View SEC Filing  
12/1/2015Gary W. KadlecPresidentSell30,000$34.93$1,047,900.00View SEC Filing  
11/3/2015Atheer A. KaddisSVPSell24,650$30.00$739,500.00View SEC Filing  
11/2/2015Gary W. KadlecPresidentSell30,000$28.03$840,900.00View SEC Filing  
10/1/2015Gary W. KadlecPresidentSell30,000$27.66$829,800.00View SEC Filing  
9/8/2015Atheer A. KaddisSVPSell12,325$37.42$461,201.50View SEC Filing  
9/1/2015Gary W. KadlecPresidentSell30,000$38.05$1,141,500.00View SEC Filing  
8/26/2015Sean WhelanCFOSell149,534$38.04$5,688,273.36142,530View SEC Filing  
3/25/2015David C DreyerDirectorBuy1,034$29.00$29,986.00View SEC Filing  
3/25/2015Jeffrey M RoweEVPSell600,000$29.00$17,400,000.00View SEC Filing  
3/25/2015Philip R HagermanCEOSell1,801,000$29.00$52,229,000.00View SEC Filing  
10/9/2014Atheer A KaddisSVPBuy4,000$13.00$52,000.00View SEC Filing  
10/9/2014Jeffrey M RoweEVPSell416,666$13.00$5,416,658.00View SEC Filing  
10/9/2014Philip R HagermanCEOSell2,916,666$13.00$37,916,658.00View SEC Filing  
10/9/2014Sean WhelanCFOBuy2,000$13.00$26,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Diplomat Pharmacy (NYSE DPLO) News Headlines

Source:
DateHeadline
Valideas Top Five Healthcare Stocks Based On Kenneth Fisher - 2 ... - NasdaqValidea's Top Five Healthcare Stocks Based On Kenneth Fisher - 2 ... - Nasdaq
www.nasdaq.com - February 19 at 8:40 AM
Diplomat Pharmacy (DPLO) Set to Announce Earnings on MondayDiplomat Pharmacy (DPLO) Set to Announce Earnings on Monday
www.americanbankingnews.com - February 19 at 4:10 AM
 Brokerages Expect Diplomat Pharmacy Inc (DPLO) Will Post Earnings of $0.17 Per Share Brokerages Expect Diplomat Pharmacy Inc (DPLO) Will Post Earnings of $0.17 Per Share
www.americanbankingnews.com - February 19 at 1:14 AM
American Renal Associates (ARA) versus Diplomat Pharmacy (DPLO) Financial SurveyAmerican Renal Associates (ARA) versus Diplomat Pharmacy (DPLO) Financial Survey
www.americanbankingnews.com - February 13 at 9:08 AM
Diplomat Pharmacy (DPLO) Coverage Initiated at Lake Street CapitalDiplomat Pharmacy (DPLO) Coverage Initiated at Lake Street Capital
www.americanbankingnews.com - February 9 at 4:34 PM
Diplomat Pharmacy (DPLO) Cut to "Hold" at Deutsche BankDiplomat Pharmacy (DPLO) Cut to "Hold" at Deutsche Bank
www.americanbankingnews.com - February 3 at 3:22 PM
$0.17 EPS Expected for Diplomat Pharmacy Inc (DPLO) This Quarter$0.17 EPS Expected for Diplomat Pharmacy Inc (DPLO) This Quarter
www.americanbankingnews.com - February 2 at 3:15 AM
Top Ranked Momentum Stocks to Buy for February 1stTop Ranked Momentum Stocks to Buy for February 1st
www.zacks.com - February 1 at 9:37 AM
FY2017 EPS Estimates for Diplomat Pharmacy Inc (DPLO) Boosted by Leerink SwannFY2017 EPS Estimates for Diplomat Pharmacy Inc (DPLO) Boosted by Leerink Swann
www.americanbankingnews.com - February 1 at 6:42 AM
ThriveRx Wins ASPEN Clinical Nutrition Team of Distinction AwardThriveRx Wins ASPEN Clinical Nutrition Team of Distinction Award
finance.yahoo.com - January 30 at 10:06 AM
Diplomat Pharmacy Inc (DPLO) Receives Average Rating of "Buy" from AnalystsDiplomat Pharmacy Inc (DPLO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 30 at 8:18 AM
Credit Suisse Group Upgrades Diplomat Pharmacy (DPLO) to "Neutral"Credit Suisse Group Upgrades Diplomat Pharmacy (DPLO) to "Neutral"
www.americanbankingnews.com - January 27 at 8:10 PM
Mizuho Analysts Give Diplomat Pharmacy (DPLO) a $25.00 Price TargetMizuho Analysts Give Diplomat Pharmacy (DPLO) a $25.00 Price Target
www.americanbankingnews.com - January 24 at 11:52 PM
Air Methods (AIRM) and Diplomat Pharmacy (DPLO) Critical ContrastAir Methods (AIRM) and Diplomat Pharmacy (DPLO) Critical Contrast
www.americanbankingnews.com - January 20 at 5:26 AM
Diplomat Pharmacy (DPLO) and MEDNAX (MD) Head to Head ReviewDiplomat Pharmacy (DPLO) and MEDNAX (MD) Head to Head Review
www.americanbankingnews.com - January 18 at 5:36 PM
This Mornings Technical Outlook on Generic Drugs Stocks -- Versartis, Diplomat Pharmacy, Mallinckrodt, and ZoetisThis Morning's Technical Outlook on Generic Drugs Stocks -- Versartis, Diplomat Pharmacy, Mallinckrodt, and Zoetis
www.bizjournals.com - January 17 at 9:31 AM
Diplomat Pharmacy Inc (DPLO) Expected to Announce Earnings of $0.17 Per ShareDiplomat Pharmacy Inc (DPLO) Expected to Announce Earnings of $0.17 Per Share
www.americanbankingnews.com - January 16 at 5:08 AM
Diplomat Dispensing Advanced Kidney Treatment, CABOMETYX®Diplomat Dispensing Advanced Kidney Treatment, CABOMETYX®
finance.yahoo.com - January 15 at 5:11 PM
Zacks.com highlights: Rice Midstream Partners, Jacobs Engineering Group, Lam Research, Diplomat Pharmacy and Forward AirZacks.com highlights: Rice Midstream Partners, Jacobs Engineering Group, Lam Research, Diplomat Pharmacy and Forward Air
finance.yahoo.com - January 15 at 9:34 AM
5 Low Leverage Stocks to Buy Amid Rate Hike Woes5 Low Leverage Stocks to Buy Amid Rate Hike Woes
finance.yahoo.com - January 12 at 9:45 AM
Cancer Genetics (CGIX) vs. Diplomat Pharmacy (DPLO) Financial ContrastCancer Genetics (CGIX) vs. Diplomat Pharmacy (DPLO) Financial Contrast
www.americanbankingnews.com - January 10 at 7:46 PM
Q1 2019 Earnings Estimate for Diplomat Pharmacy Inc (DPLO) Issued By William BlairQ1 2019 Earnings Estimate for Diplomat Pharmacy Inc (DPLO) Issued By William Blair
www.americanbankingnews.com - January 9 at 11:02 PM
Diplomat Pharmacy (DPLO) Price Target Raised to $26.00Diplomat Pharmacy (DPLO) Price Target Raised to $26.00
www.americanbankingnews.com - January 8 at 11:18 AM
Reviewing TeamHealth (TMH) & Diplomat Pharmacy (DPLO)Reviewing TeamHealth (TMH) & Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - January 7 at 1:10 AM
Insider Bets Paying Off At DPLO As New 52-Week High ReachedInsider Bets Paying Off At DPLO As New 52-Week High Reached
www.nasdaq.com - January 6 at 9:39 AM
Diplomat Pharmacy (DPLO) Reiterates 2017 Guidance & Offers Preliminary 2018 Outlook; Announces CEO Transition - StreetInsider.comDiplomat Pharmacy (DPLO) Reiterates 2017 Guidance & Offers Preliminary 2018 Outlook; Announces CEO Transition - StreetInsider.com
www.streetinsider.com - January 5 at 4:58 PM
Here's Why Diplomat Pharmacy Surged as Much as 11.1% TodayHere's Why Diplomat Pharmacy Surged as Much as 11.1% Today
finance.yahoo.com - January 5 at 4:58 PM
Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 OutlookDiplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook
finance.yahoo.com - January 5 at 9:45 AM
Diplomat Initiates CEO Transition; Reaffirms 2017 Guidance and Provides Preliminary 2018 OutlookDiplomat Initiates CEO Transition; Reaffirms 2017 Guidance and Provides Preliminary 2018 Outlook
finance.yahoo.com - January 5 at 9:45 AM
Diplomat Pharmacy Inc (DPLO) Given Consensus Rating of "Buy" by BrokeragesDiplomat Pharmacy Inc (DPLO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 5 at 8:28 AM
Financial Analysis: Joint (JYNT) and Diplomat Pharmacy (DPLO)Financial Analysis: Joint (JYNT) and Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - January 5 at 3:32 AM
GNC Holdings (GNC) Looks Good: Stock Adds 10.2% in SessionGNC Holdings (GNC) Looks Good: Stock Adds 10.2% in Session
finance.yahoo.com - January 2 at 9:35 AM
Can Diplomat Pharmacy (DPLO) Keep the Earnings Streak Alive This Quarter?Can Diplomat Pharmacy (DPLO) Keep the Earnings Streak Alive This Quarter?
finance.yahoo.com - January 2 at 9:35 AM
Zacks: Analysts Anticipate Diplomat Pharmacy Inc (DPLO) Will Post Quarterly Sales of $1.17 BillionZacks: Analysts Anticipate Diplomat Pharmacy Inc (DPLO) Will Post Quarterly Sales of $1.17 Billion
www.americanbankingnews.com - January 1 at 6:40 PM
$0.16 Earnings Per Share Expected for Diplomat Pharmacy Inc (DPLO) This Quarter$0.16 Earnings Per Share Expected for Diplomat Pharmacy Inc (DPLO) This Quarter
www.americanbankingnews.com - December 30 at 9:12 AM
Q1 2018 EPS Estimates for Diplomat Pharmacy Inc Increased by William Blair (DPLO)Q1 2018 EPS Estimates for Diplomat Pharmacy Inc Increased by William Blair (DPLO)
www.americanbankingnews.com - December 25 at 6:30 AM
Cancer Genetics (CGIX) and Diplomat Pharmacy (DPLO) Financial ContrastCancer Genetics (CGIX) and Diplomat Pharmacy (DPLO) Financial Contrast
www.americanbankingnews.com - December 24 at 11:52 PM
Critical Contrast: Kindred Healthcare (KND) & Diplomat Pharmacy (DPLO)Critical Contrast: Kindred Healthcare (KND) & Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - December 24 at 5:15 AM
Diplomat Completes Acquisition of LDI Integrated Pharmacy Services, Secures ...Diplomat Completes Acquisition of LDI Integrated Pharmacy Services, Secures ...
www.prnewswire.com - December 21 at 5:12 PM
Stocks Flashing Renewed Technical Strength: Diplomat PharmacyStocks Flashing Renewed Technical Strength: Diplomat Pharmacy
finance.yahoo.com - December 20 at 5:10 PM
Diplomat Completes Acquisition of LDI Integrated Pharmacy Services, Secures New Credit FacilitiesDiplomat Completes Acquisition of LDI Integrated Pharmacy Services, Secures New Credit Facilities
finance.yahoo.com - December 20 at 5:10 PM
Diplomat to Participate in 36th Annual J.P. Morgan Healthcare ConferenceDiplomat to Participate in 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 20 at 5:10 PM
ETFs with exposure to Diplomat Pharmacy, Inc. : December 19, 2017ETFs with exposure to Diplomat Pharmacy, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 5:12 PM
Diplomat Pharmacy, Inc. :DPLO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 18, 2017Diplomat Pharmacy, Inc. :DPLO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 18, 2017
finance.yahoo.com - December 18 at 5:11 PM
 Brokerages Expect Diplomat Pharmacy, Inc. (DPLO) Will Post Quarterly Sales of $1.17 Billion Brokerages Expect Diplomat Pharmacy, Inc. (DPLO) Will Post Quarterly Sales of $1.17 Billion
www.americanbankingnews.com - December 15 at 4:50 PM
FY2019 EPS Estimates for Diplomat Pharmacy, Inc. (DPLO) Increased by AnalystFY2019 EPS Estimates for Diplomat Pharmacy, Inc. (DPLO) Increased by Analyst
www.americanbankingnews.com - December 13 at 11:28 PM
Stocks To Watch: Diplomat Pharmacy Sees Relative Strength Rating Jump To 83Stocks To Watch: Diplomat Pharmacy Sees Relative Strength Rating Jump To 83
finance.yahoo.com - December 12 at 5:37 PM
Update in Lawsuit for Investors in Diplomat Pharmacy Inc (NYSE: DPLO) shares announced by Shareholders Foundation - GlobeNewswire (press release)Update in Lawsuit for Investors in Diplomat Pharmacy Inc (NYSE: DPLO) shares announced by Shareholders Foundation - GlobeNewswire (press release)
globenewswire.com - December 12 at 10:05 AM
Diplomat Pharmacy, Inc. (DPLO) Forecasted to Post FY2017 Earnings of $0.86 Per ShareDiplomat Pharmacy, Inc. (DPLO) Forecasted to Post FY2017 Earnings of $0.86 Per Share
www.americanbankingnews.com - December 12 at 7:40 AM
Diplomat Adds Chris Luthin as Executive Vice PresidentDiplomat Adds Chris Luthin as Executive Vice President
finance.yahoo.com - December 11 at 5:23 PM

SEC Filings

Diplomat Pharmacy (NYSE:DPLO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Diplomat Pharmacy (NYSE:DPLO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Diplomat Pharmacy (NYSE DPLO) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.